



Clinical trial results:

Investigation of a novel intervention in Acute HIV infection (AHI) on long term latent HIV reservoir size: A pilot study of antiretroviral therapy plus immunoglobulin in AHI

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2011-001982-42 |
| Trial protocol | GB |
| Global end of trial date | 30 March 2015 |

Results information

| | |
|-----------------------------------|--|
| Result version number | v1 (current) |
| This version publication date | 06 December 2018 |
| First version publication date | 06 December 2018 |
| Summary attachment (see zip file) | FINAL STUDY REPORT (ivIG AHI GSTT report 20032017.pdf) |

Trial information

Trial identification

| | |
|-----------------------|------|
| Sponsor protocol code | J004 |
|-----------------------|------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Guy's and St Thomas' NHS Foundation Trust |
| Sponsor organisation address | Great Maze Pond, London, United Kingdom, SE19RT |
| Public contact | Julie Fox, Guy's & St. Thomas' NHS Foundation Trust, +44 207188 2643, julie.fox@gstt.nhs.uk |
| Scientific contact | Julie Fox, Guy's & St. Thomas' NHS Foundation Trust, +44 207188 2643, julie.fox@gstt.nhs.uk |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|---------------|
| Analysis stage | Final |
| Date of interim/final analysis | 30 March 2015 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 30 March 2015 |
| Global end of trial reached? | Yes |
| Global end of trial date | 30 March 2015 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To investigate whether reactivation of HIV using immunoglobulin in individuals with AHI and virologically suppressed with ART, will reduce HIV viral reservoir at week 48.

Protection of trial subjects:

Safety blood tests (FBC, Urea and electrolytes and liver function tests) and adherence review are incorporated into the visit schedule. Any abnormalities or concerns will be addressed immediately and reported.

Background therapy:

NONE

Evidence for comparator:

INCLUSION CRITERIA

Males and females aged between 18-65 years (inclusive).

HIV antibody negative with p24/PCR DNA positive

OR

HIV antibody positive with a previous HIV negative test in the preceding 3 months

OR

Health Protection Agency HIV incident virus assay (estimating virus acquired within 3 months)

Ability and willingness to provide informed consent

| | |
|---|--------------|
| Actual start date of recruitment | 05 July 2012 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United Kingdom: 10 |
| Worldwide total number of subjects | 10 |
| EEA total number of subjects | 10 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |

| | |
|---------------------------|----|
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 10 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Participants were recruited from one clinical site in London between 2013 to 2015

Pre-assignment

Screening details:

Males and females aged between 18-65 years (inclusive).

2) HIV antibody negative with p24/PCR DNA positive

OR

HIV antibody positive with a previous HIV negative test in the preceding 3 months

OR

Health Protection Agency HIV incident virus assay (estimating virus acquired within 3 months)

3) Ability and willingness to provide informed consent

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Blinding implementation details:

At week 20 post commencement on ART therapy, participants are randomized to receive 5 days treatment with IVIG or no IVIG.

Arms

| | |
|------------------------------|---------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | ARM B - IVIG Intervention |

Arm description:

Participants randomised at week 20 post commencement on ART to receive 30g IVIG per day for five days

| | |
|--|-----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | IVIG |
| Investigational medicinal product code | OCTAGAM |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

30mg per day for 5 days

| | |
|------------------|------------------------------|
| Arm title | ARM A - NO IVIG INTERVENTION |
|------------------|------------------------------|

Arm description:

Randomised at 20 weeks post commencement on ante retro viral therapy to NOT receive IVIG

| | |
|---|---------|
| Arm type | CONTROL |
| No investigational medicinal product assigned in this arm | |

| Number of subjects in period 1 | ARM B - IVIG Intervention | ARM A - NO IVIG INTERVENTION |
|---------------------------------------|------------------------------|---------------------------------|
| Started | 5 | 5 |
| Completed | 5 | 5 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | Overall Trial |
|-----------------------|---------------|

Reporting group description: -

| Reporting group values | Overall Trial | Total | |
|---|---------------|-------|--|
| Number of subjects | 10 | 10 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 10 | 10 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 0 | 0 | |
| Male | 10 | 10 | |

End points

End points reporting groups

| | |
|---|------------------------------|
| Reporting group title | ARM B - IVIG Intervention |
| Reporting group description: Participants randomised at week 20 post commencement on ART to receive 30g IVIG per day for five days | |
| Reporting group title | ARM A - NO IVIG INTERVENTION |
| Reporting group description: Randomised at 20 weeks post commencement on ante retro viral therapy to NOT receive IVIG | |

Primary: Primary Endpoint

| | |
|---|---------------------------------|
| End point title | Primary Endpoint ^[1] |
| End point description: HIV viral reservoir - change in HIV proviral DNA quantification between enrolment and week 48 | |
| End point type | Primary |
| End point timeframe: 48 weeks post commencement on ART | |
| Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: See attached report for results | |

| End point values | ARM B - IVIG Intervention | ARM A - NO IVIG INTERVENTION | | |
|-----------------------------|---------------------------|------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5 | 5 | | |
| Units: whole | 5 | 5 | | |

| | |
|-----------------------------------|---|
| Attachments (see zip file) | AHI RESULTS/ivIG AHI GSTT report 20032017.pdf |
|-----------------------------------|---|

Statistical analyses

No statistical analyses for this end point

Secondary: Secondary Endpoint

| | |
|---|--------------------|
| End point title | Secondary Endpoint |
| End point description: Secondary outcome measures: measured as a comparison across arms between enrolment and week 48. a. Changes in CD8 T-cell activation: the percentage of CD3+ CD8+ cells expressing CD38+ b. Gut permeability: 16S DNA c. Host gene expression profiling d. Clinical outcome: CD4 T-cell counts, CD4 T cell decline, HIV RNA e. Immunological markers of T cell exhaustion: HLA-DR and PD-1 f. Inflammation (D-dimer) | |
| End point type | Secondary |

End point timeframe:

Until 48 weeks post commencement on ART

| End point values | ARM B - IVIG Intervention | ARM A - NO IVIG INTERVENTION | | |
|-----------------------------|------------------------------|------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5 | 5 | | |
| Units: whole | 5 | 5 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Duration of the study

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 17.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|------------------------------|
| Reporting group title | ARM A - NO IVIG INTERVENTION |
|-----------------------|------------------------------|

Reporting group description: -

| | |
|-----------------------|---------------------------|
| Reporting group title | ARM B - IVIG INTERVENTION |
|-----------------------|---------------------------|

Reporting group description: -

| Serious adverse events | ARM A - NO IVIG INTERVENTION | ARM B - IVIG INTERVENTION | |
|---|------------------------------|---------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 5 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | ARM A - NO IVIG INTERVENTION | ARM B - IVIG INTERVENTION | |
|---|------------------------------|---------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 5 (40.00%) | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cold | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 5 (20.00%) | |
| occurrences (all) | 0 | 1 | |
| Infections and infestations | | | |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 5 (20.00%) | |
| occurrences (all) | 0 | 1 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------|---|
| 15 May 2014 | Change in CI (to Julie Fox) * Update label to reflect change back to JF as CI * Multi-centre to single centre * Remove Imperial site *Clarification added to Hep B exclusion criteria |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported